{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:25:56Z","timestamp":1760235956913,"version":"build-2065373602"},"reference-count":49,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background: The current treatment landscape of early stage lung cancer is rapidly evolving, particularly in EGFR mutant non-small cell lung cancer (NSCLC), where target therapy is moving to early stages. In the current review, we collected the available data exploring the impact of EGFR targeting in both neoadjuvant and adjuvant settings, underlying lights and shadows and discussing the existing open issues. Methods: We performed a comprehensive search using PubMed and the proceedings of major international meetings to identify neoadjuvant\/adjuvant trials with EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. Results: Limited data are available so far about the activity\/efficacy of neoadjuvant TKIs in EGFR mutant NSCLC, with only modest downstaging and pathological complete response rates reported. Differently, the ADAURA trial already proposed osimertinib as a potential new standard of care in resected NSCLC harboring an activating EGFR mutation. Conclusion: Anticipating targeted therapy to early stage EGFR mutant NSCLC presents great opportunities but also meaningful challenges in the current therapeutic\/diagnostic pathway of lung cancer care. Appropriate endpoint(s) selection for clinical trials, disease progression management, patients\u2019 and treatment selection, as well as need to address the feasibility of molecular profiling anticipation, represent crucial issues to face before innovation can move to early stages.<\/jats:p>","DOI":"10.3390\/cells10102685","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T08:41:49Z","timestamp":1633682509000},"page":"2685","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1981-5499","authenticated-orcid":false,"given":"Lorenzo","family":"Belluomini","sequence":"first","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Teresa","family":"Riva","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-4499","authenticated-orcid":false,"given":"Michele","family":"Simbolo","sequence":"additional","affiliation":[{"name":"Section of Pathology, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Nocini","sequence":"additional","affiliation":[{"name":"Otolaryngology\u2014Head and Neck Surgery Department, University of Verona Hospital Trust, 37126 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-9771","authenticated-orcid":false,"given":"Ilaria","family":"Trestini","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2439-4799","authenticated-orcid":false,"given":"Alice","family":"Avancini","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Tregnago","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-2599","authenticated-orcid":false,"given":"Miriam Grazia","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00100 Rome, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, 00100 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Caldart","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Dodi","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cali\u00f2","sequence":"additional","affiliation":[{"name":"Section of Pathology, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2333-704X","authenticated-orcid":false,"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00100 Rome, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, 00100 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-739X","authenticated-orcid":false,"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[{"name":"Section of Pathology, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Menis","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-4874","authenticated-orcid":false,"given":"Sara","family":"Pilotto","sequence":"additional","affiliation":[{"name":"Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JTO.0b013e3181c5920c","article-title":"Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database survey","volume":"5","author":"Morgensztern","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"LBA7500","DOI":"10.1200\/jco.2012.30.18_suppl.lba7500","article-title":"LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations","volume":"30","author":"Yang","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"(2014). Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data. Lancet, 383, 1561\u20131571.","DOI":"10.1016\/S0140-6736(13)62159-5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"Np5","DOI":"10.1177\/0300891618775204","article-title":"Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences","volume":"104","author":"Mazzoni","year":"2018","journal-title":"Tumori"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non\u2013Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study","volume":"37","author":"Zhong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"300060519887275","DOI":"10.1177\/0300060519887275","article-title":"Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients","volume":"48","author":"Xiong","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-015-0151-3","article-title":"Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status","volume":"8","author":"Zhong","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1158\/1078-0432.CCR-10-2102","article-title":"Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene","volume":"17","author":"Rizvi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","article-title":"Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study","volume":"161","author":"Zhang","year":"2021","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/JCO.2021.39.15_suppl.8502","article-title":"CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non\u2013small cell lung cancer","volume":"39","author":"Wu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","article-title":"Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study","volume":"31","author":"Goss","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.18.00131","article-title":"SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer","volume":"37","author":"Pennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): A randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1200\/JCO.2020.38.15_suppl.9005","article-title":"CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation\u2014Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial","volume":"38","author":"Wu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): A randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1245\/s10434-014-3586-9","article-title":"Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: A randomized, phase II study","volume":"21","author":"Li","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2021.39.15_suppl.8501","article-title":"Adjuvant gefitinib versus cisplatin\/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial","volume":"39","author":"Tada","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sun, L., Guo, Y.-J., Song, J., Wang, Y.-R., Zhang, S.-L., Huang, L.-T., Zhao, J.-Z., Jing, W., Han, C.-B., and Ma, J.-T. (2021). Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.586596"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S578","DOI":"10.1016\/j.jtho.2019.08.1209","article-title":"P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer","volume":"14","author":"Rotow","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tsuboi, M., Weder, W., Escriu, C., Blakely, C., He, J., Dacic, S., Yatabe, Y., Zeng, L., Walding, A., and Chaft, J.E. (2021). Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol.","DOI":"10.2217\/fon-2021-0549"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021","volume":"19","author":"Ettinger","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jtho.2021.01.1628","article-title":"Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy","volume":"16","author":"Aredo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1356145","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_41","unstructured":"Piper-Vallillo, A.J., Mak, R., Lanuti, M.M.A., Rotow, J., Janne, P., Mino-Kenudson, M., Swanson, S., Wright, C., and Kozono, D. (2021, January 17\u201320). The ASCENT trial: A phase II study of neoadjuvant\/adjuvant afatinib, chemoradiation +\/\u2212 surgery for stage III EGFR-mutant NSCLC. Proceedings of the Presented at International Association for the Study of Lung Cancer 2021 Targeted Therapies of Lung Cancer Meeting, Worldwide Virtual Event."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Roper, N., Brown, A.L., Wei, J.S., Pack, S., Trindade, C., Kim, C., Restifo, O., Gao, S., Sindiri, S., and Mehrabadi, F. (2020). Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Rep. Med., 1.","DOI":"10.1016\/j.xcrm.2020.100007"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-20-5026","article-title":"Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e17514","DOI":"10.1200\/jco.2011.29.15_suppl.e17514","article-title":"International tailored chemotherapy adjuvant trial: ITACA trial","volume":"29","author":"Novello","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"103311","DOI":"10.1016\/j.critrevonc.2021.103311","article-title":"Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021","volume":"161","author":"Pisapia","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/JCO.2021.39.15_suppl.8517","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC","volume":"39","author":"Gale","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1016\/S1556-0864(21)01935-3","article-title":"93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy","volume":"16","author":"Spigel","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103459","DOI":"10.1016\/j.critrevonc.2021.103459","article-title":"How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review","volume":"166","author":"Torres","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2021.39.15_suppl.9004","article-title":"Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices","volume":"39","author":"Robert","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/10\/2685\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:10:20Z","timestamp":1760166620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/10\/2685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cells10102685"],"URL":"https:\/\/doi.org\/10.3390\/cells10102685","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2021,10,7]]}}}